| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_050fc7b82c5d17d9aeb63a7cdcc546b3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R2001-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R2001-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55594
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-521 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-205 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-32 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-04 |
| filingDate |
2018-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_964cef6ab8a5d764f6054ab46916ecb6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb45cdcbf7c4a7581d13d4286fe148ac |
| publicationDate |
2022-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11331350-B2 |
| titleOfInvention |
Use of Mycobacterium paragordonae for cancer immunotherapy |
| abstract |
The present invention relates to an anti-cancer regulatory response and immunotherapy by Mycobacterium paragordonae ( M. paragordonae ). Mycobacterium paragordonae according to an aspect has cancer cytotoxicity mediated by natural killer cells or T cells as well as cytotoxicity against cancer cells, and inhibits activation of cancer cytotoxicity regulatory T cells of macrophages or dendritic cells to induce an immune response, thereby inhibiting tumor formation and thus being useful for a cancer immunotherapeutic agent. |
| priorityDate |
2017-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |